Research digest / anxiolytic + nootropic peptide

Selank is a tuftsin-analog peptide studied as a non-sedating anxiolytic and nootropic.

Here is the whole research picture in plain English — what the studies actually measured, what people report, and the honest gaps — every number cited.

Abstract blurple waveform settling from chaotic to calm with a soft seven-node peptide chain on a charcoal background

The short version

Here is Selank in plain words: a tiny lab-made peptide (a short chain of seven amino acids) that researchers built in Russia to calm anxiety without the foggy, sedated feeling that older anxiety drugs cause. It is a stabilized copy of tuftsin (a natural calming-and-immune peptide your own antibodies release), tweaked so the body breaks it down more slowly.

In animal studies and a handful of small human trials, Selank lowered anxiety and nudged learning and memory in the right direction, and it did this through a different route than benzodiazepines — partly by quieting the brain's GABA system, partly by protecting the body's own feel-good opioid signals [1][2]. Real-world users mostly describe "calm but still sharp," though a fair number feel little or nothing.

The big honest catch: almost all the human evidence comes from one country, Selank is not FDA-approved, and what is sold elsewhere is a research chemical. What people report — the upsides and the downsides — is on the effects page.

What the Selank research actually shows

Selank's calming effect is real in the lab, and it does not work like a sedative. A 2018 review concluded that Selank acts as a positive allosteric modulator of GABA-receptor binding — meaning it doesn't flip the brain's main "calm down" switch directly, it makes that switch easier to flip — and that its action is subtype-selective and dose-dependent, which is fundamentally different from how benzodiazepines work [1].

The second engine is the body's own pain-and-stress relief system. In human plasma in the lab, Selank blocked the enzymes that chew up enkephalins (the body's natural opioid-like calming molecules) with a half-maximal effect around 15 µM [2]. Slow the breakdown, and those calming signals last longer.

It also reaches into neuroplasticity: intranasal Selank raised BDNF (a protein that helps brain cells grow and adapt) in the rat hippocampus [3], and a single 300 µg/kg dose shifted the expression of dozens of GABA-system genes in rat frontal cortex — 45 genes at one hour, 22 at three hours — in the same direction GABA itself produces [4]. None of this is a stimulant push; it is the brain's own calm pathways being supported.

Selank peptide: where it came from

Selank (also called TP-7) was created by the Institute of Molecular Genetics of the Russian Academy of Sciences with the Zakusov Institute of Pharmacology. Its full sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro — the natural tetrapeptide tuftsin with a Pro-Gly-Pro "tail" bolted on to slow enzymatic breakdown [6].

From the late 1990s onward, Russian groups advanced it into clinical study for generalized anxiety disorder and anxiety-asthenic (fatigue-plus-anxiety) conditions. In those trials, intranasal Selank produced an anxiolytic effect comparable to a benzodiazepine but without the sedation, cognitive dulling, or withdrawal [6]. That is the headline that made it famous — and it is also a single-region finding, which this site keeps front and center. For the full molecule and study list, see Selank research.

A calmer kind of anxiety research

Most of what made Selank interesting is the contrast. Benzodiazepines calm anxiety by sedating you and carry a real dependence and withdrawal risk. SSRIs take weeks and can flatten mood. Selank, in the research record, lowered anxiety while keeping animals and patients alert — and across rodent studies it reduced both inherited anxiety and stress-provoked anxiety [13].

It is also being studied somewhere most anxiolytics never go: addiction and withdrawal. Selank reduced anxiety during modeled alcohol withdrawal in rats [8], curbed ethanol-driven hyperactivity in mice [9], and in the most recent study in this digest (2022) it eased the aversive signs of morphine withdrawal in rats [11]. That withdrawal angle is explored on its own page — see Selank withdrawal.

What to read next

This is an editorial digest, not a clinic and not a store. If you want the mechanism and the study-by-study detail, start with Selank research. If you want the honest human picture — what people report and who should be careful — go to Selank effects. For the doses used in studies (research context only, never a recommendation) see the dosage page, and every source is listed in full on Selank references. Curious how it stacks up against its better-known sibling? Read Selank vs Semax.